Table 3.
Costs for patients eligible for E2 medicines (median (IQR)) | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
---|---|---|---|---|---|---|
Annual healthcare expenditures* (median (IQR)) | ||||||
Total healthcare costs | $67 515 ($12 592, $218 725) | $87 706 ($12 990, $235 668) | $55 749 ($12 990, $235 668) | $72 184 ($16 252, $215 144) | $65 123 ($19 521, $263 784) | $70 275 ($22 946, $239 868) |
All medicines | $54 992 ($10 648, $150 343) | $68 572 ($21 788, $205 104) | $44 395 ($13 716, $120 051) | $50 522 ($16 829, $157 273) | $49 170 ($17 773, $143 529) | $53 037 ($9067, $134 231) |
E2 medicines | $50 787 ($10 327, $127 922) | $63 862 ($21 223, $172 328) | $40 628 ($13 346, $104 496) | $44 931 ($14 457, $134 761) | $44 831 ($17 363, $119 392) | $48 176 ($8827, $111 810) |
Non-E2 medicines | $4410 ($283, $23 799) | $5173 ($321, $22 420) | $3410 ($369, $17 548) | $5387 ($371, $22 512) | $4219 ($409, $24 136) | $5186 ($565, $25 574) |
Other costs | $12 250 ($2352, $40 202) | $20 713 ($2341, $45 206) | $10 657 ($1770, $34 254) | $21 661 ($2786, $64 862) | $15 963 ($2572, $59 841) | $16 913 ($2175, $61 997) |
Expenditures per patient* (median (IQR)) | ||||||
Number of eligible patients | 273 | 301 | 315 | 362 | 371 | 402 |
Total healthcare costs | $4180 ($2033, $9100) | $4391 ($2323, $8216) | $3192 ($1385, $6250) | $3267 ($1340, $6359) | $3361 ($1544, $7085) | $3197 ($1248, $6198) |
All medicines | $3326 ($1278, $5959) | $3244 ($1899, $6704) | $2314 ($1031, $4830) | $2365 ($1092, $4799) | $2389 ($1232, $5168) | $2291 ($1175, $5539) |
E2 medicines† | $3083 ($1081, $4660) | $3193 ($1111, $5233) | $2102 ($1031, $4164) | $2180 ($1139, $4300) | $2167 ($951, $4108) | $2071 ($1081, $4660) |
Non-E2 medicines | $314 ($50, $911) | $311 ($64, $784) | $254 ($49, $856) | $196 ($49, $700) | $266 ($43, $808) | $220 ($40, $741) |
Other costs | $854 ($269, $1793) | $914 ($277, $1554) | $878 ($158, $1359) | $902 ($133, $1442) | $980 ($133, $1432) | $916 ($103, $1330) |
*(US$, year 2014 value).
†Central procurement prices were used to calculate costs of E2 medicines after policy implementation.